ASP5878
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ASP5878, covering 2024-10-31 to 2024-10-31. Get the full timeline:
Most recent: Clinical Trial Update: An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors [Phase 1]